| References |
|
|
Aerts JM,
Hollak CE,
Boot RG et al.
(2006)
Substrate reduction therapy of glycosphingolipid storage disorders.
Journal of Inherited Metabolic Disease
29:
449456.
|
|
|
Alber T
(1989)
Mutational effects on protein stability.
Annual Review of Biochemistry
58:
765798.
|
|
|
Brown CA and
Mahuran DJ
(1993)
-Hexosaminidase isozymes from cells co-transfected with and cDNA constructs: analysis of subunit missense mutation associated with the adult form of Tay-Sachs disease.
American Journal of Human Genetics
53:
497508.
|
|
|
Cachon-Gonzalez MB,
Wang SZ,
Lynch A et al.
(2006)
Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
Proceedings of the National Academy of Sciences of the USA
103:
1037310378.
|
|
|
Chen B,
Rigat B,
Curry C et al.
(1999)
Structure of the GM2A gene: identification of an exon 2 nonsense mutation and a naturally occurring transcript with an in-frame deletion of exon 2.
American Journal of Human Genetics
65:
7787.
|
|
|
other
Clarke JTR,
Mahuran DJ,
Sathe S et al.
(2010) Open-label phase I/II clinical trial of pyrimethamine for the treatment of chronic GM2 gangliosidosis. Molecular Genetics and Metabolism (in press).
|
|
|
Conzelmann E and
Sandhoff K
(1978)
AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2.
Proceedings of the National Academy of Sciences of the USA
75:
39793983.
|
|
|
Desnick RJ
(2004)
Enzyme replacement and enhancement therapies for lysosomal diseases.
Journal of Inherited Metabolic Disease
27:
385410.
|
|
|
Dill KD and
Shortle D
(1991)
Denatured states of proteins.
Annual Review of Biochemistry
60:
795825.
|
|
|
Edgington SM
(1992)
Rites of passage: moving biotech proteins through the ER.
Biotechnology
10:
14131420.
|
|
|
book
Gravel RA,
Clarke JTR,
Kaback MM et al.
(1995)
"The GM2 gangliosidoses".
In: Scriver CR,
Beaudet AL,
Sly WS and
Valle D (eds)
The Metabolic and Molecular Basis of Inherited Disease, vol.
2,
pp. 28392879.
New York: McGraw-Hill.
|
|
|
Henrissat B and
Bairoch A
(1993)
New families in the classification of glycosyl hydrolases based on amino acid sequence similarities.
Biochemical Journal
293:
781788.
|
|
|
Hou Y,
Vocadlo D,
Withers S et al.
(2000)
Role of beta Arg211 in the active site of human beta-hexosaminidase B.
Biochemistry
39:
62196227.
|
|
|
Huang JQ,
Trasler JM,
Igdoura S et al.
(1997)
Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Human Molecular Genetics
6:
18791885.
|
|
|
Jeyakumar M,
Butters TD,
Cortina-Borja M et al.
(1999)
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Proceedings of the National Academy of Sciences of the USA
96:
63886393.
|
|
|
Kresse H,
Fuchs W,
Glossl J et al.
(1981)
Liberation of N-acetylglucosamine-6-sulfate by human beta-N-acetylhexosaminidase A.
Journal of Biological Chemistry
256:
1292612932.
|
|
|
Lemieux MJ,
Mark BL,
Cherney MM et al.
(2006)
Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of G(M2) ganglioside hydrolysis.
Journal of Molecular Biology
359:
913929.
|
|
|
Maegawa GH,
Banwell BL,
Blaser S et al.
(2009a)
Substrate reduction therapy in juvenile GM2 gangliosidosis.
Molecular Genetics and Metabolism
98:
215224.
|
|
|
Maegawa GHB,
Tropak M,
Butner J et al.
(2007)
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
Journal of Biological Chemistry
282:
91509161.
|
|
|
Maegawa GHB,
Tropak MB,
Buttner JD et al.
(2009b)
Identification and characterization of ambroxol as an enzyme-enhancement agent for Gaucher disease.
Journal of Biological Chemistry
284:
2350223516.
|
|
|
Mahuran DJ
(1998)
The GM2 activator protein, its roles as a co-factor in GM2 hydrolysis and as a general glycolipid transport protein.
Biochimica et Biophysica Acta
1393:
118.
|
|
|
Mahuran DJ
(1999)
Biochemical consequences of mutations causing the GM2 gangliosidoses.
Biochimica et Biophysica Acta
1455:
105138.
|
|
|
Maier T,
Strater N,
Schuette CG et al.
(2003)
The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease.
Journal of Molecular Biology
328:
669681.
|
|
|
Mark BL,
Mahuran DJ,
Cherney MM et al.
(2003)
Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.
Journal of Molecular Biology
327:
10931109.
|
|
|
Martin DR,
Krum BK,
Varadarajan GS et al.
(2004)
An inversion of 25 base pairs causes feline GM2 gangliosidosis variant.
Experimental Neurology
187:
3037.
|
|
|
Ni M and
Lee AS
(2007)
ER chaperones in mammalian development and human diseases.
FEBS Letters
581:
36413651.
|
|
|
Pons T,
Olmea O,
Chinea G et al.
(1998)
Structural model for family 32 of glycosyl-hydrolase enzymes.
Proteins
33:
383395.
|
|
|
Shapiro BE,
Pastores GM,
Gianutsos J et al.
(2009)
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
Genetics in Medicine
11:
425433.
|
|
|
Sharma R,
Deng H,
Leung A et al.
(2001)
Identification of the 6-sulfate binding site unique to -subunit-containing isozymes of human -hexosaminidase.
Biochemistry
40:
54405446.
|
|
|
Tews I,
Perrakis A,
Oppenheim A et al.
(1996)
Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease.
Nature Structural Biology
3:
638648.
|
|
|
Triggs-Raine BL,
Akerman BR,
Clarke JT et al.
(1991)
Sequence of DNA flanking the exons of the HEXA gene, and identification of mutations in Tay-Sachs disease.
American Journal of Human Genetics
49:
10411054.
|
|
|
Trombetta ES and
Parodi AJ
(2003)
Quality control and protein folding in the secretory pathway.
Annual Review of Cell & Developmental Biology
19:
649676.
|
|
|
Tropak MB,
Blanchard J,
Withers SG et al.
(2007)
High-throughput screening for novel human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones.
Chemistry and Biology
14:
153164.
|
|
|
Tropak MB,
Bukovac SW,
Rigat BA et al.
(2010)
A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.
Glycobiology
20:
356365.
|
|
|
Tropak MB,
Kornhaber GJ,
Rigat BA et al.
(2008)
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on -glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.
ChemBioChem
9:
26502662.
|
|
|
Tropak MB and
Mahuran D
(2007)
Lending a helping hand, screening chemical libraries for compounds that enhance -hexosaminidase A activity in GM2 gangliosidosis cells.
FEBS Journal
274:
49514961.
|
|
|
Tropak MB,
Reid S,
Guiral M et al.
(2004)
Pharmacological enhancement of -hexosaminidase activity in fibroblasts from adult Tay-Sach and Sandhoff patients.
Journal of Biological Chemistry
279:
1347813487.
|
|
|
Wakamatsu N,
Kobayashi H,
Miyatake T et al.
(1992)
A novel exon mutation in human -hexosaminidase subunit gene affecting the 3¢ splice site selection.
Journal of Biological Chemistry
267:
24062413.
|
|
|
Wendeler M,
Werth N,
Maier T et al.
(2006)
The enzyme-binding region of human GM2-activator protein.
FEBS Journal
273:
982991.
|
|
|
Williams SJ,
Mark BL,
Vocadlo DJ et al.
(2002)
Aspartate 313 in the Streptomyces plicatus hexosaminidase plays a critical role in substrate-assisted catalysis by orienting the 2-acetamido group and stabilizing the transition state.
Journal of Biological Chemistry
277:
4005540065.
|
|
|
Wright CS,
Li SC and
Rastinejad F
(2000)
Crystal structure of human GM2-activator protein with a novel beta-cup topology.
Journal of Molecular Biology
304:
411422.
|
|
|
Wu BM,
Tomatsu S,
Fukuda S et al.
(1994)
Overexpression rescues the mutant phenotype of L176F mutation causing beta-glucuronidase deficiency mucopolysaccharidosis in two Mennonite siblings.
Journal of Biological Chemistry
269:
2368123688.
|
|
|
Zarghooni M,
Bukovac S,
Tropak M et al.
(2004)
An alpha-subunit loop structure is required for GM2 activator protein binding by beta-hexosaminidase A.
Biochemical & Biophysical Research Communications
324:
10481052.
|
| Further Reading |
|
|
Ballabio A and
Gieselmann V
(2009)
Lysosomal disorders: from storage to cellular damage.
Biochimica et Biophysica Acta
1793:
684696.
|
|
|
Bernales S,
Papa FR and
Walter P
(2006)
Intracellular signaling by the unfolded protein response.
Annual Review of Cell & Developmental Biology
22:
487508.
|
|
|
Lee JH,
Yu WH,
Kumar A et al.
(2010)
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations.
Cell
141:
11461158.
|
|
|
Settembre C,
Fraldi A,
Jahreiss L et al.
(2008)
A block of autophagy in lysosomal storage disorders.
Human Molecular Genetics
17:
119129.
|
|
|
Vellodi A
(2005)
Lysosomal storage disorders.
British Journal of Haematology
128:
413431.
|
|
|
Winslow AR and
Rubinsztein DC
(2008)
Autophagy in neurodegeneration and development.
Biochimica et Biophysica Acta
1782:
723729.
|
|
|
Wiseman RL,
Powers ET,
Buxbaum JN et al.
(2007)
An adaptable standard for protein export from the endoplasmic reticulum.
Cell
131:
809821.
|